At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 25 enrolled
Drug / intervention
Sacituzumab Govitecan-hiydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label Rollover Study to Evaluate Long-Term Safety in Subjects With Metastatic Solid Tumors That Are Benefiting From Continuation of Therapy With Sacituzumab Govitecan
In Brief
A Phase 4 clinical trial evaluating Sacituzumab Govitecan-hiy for Metastatic Solid Tumors. Completed, enrolled 25 participants across 21 sites in 3 countries.
Detailed Summary
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Solid Tumors
CountriesBelgium, France, United States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartAug 2020
Primary CompletionOct 2024
TodayJul 2026
First PostedMar 24, 2020
Enrollment StartAug 4, 2020
Primary CompletionOct 18, 2024
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 6.3 years ago
Interventions
Sacituzumab Govitecan-hiydrug
Administered intravenously